BPI Europe Highlights
More.jpg?width=700&auto=webp&quality=80&disable=upscale)
UCB says it built out its internal capabilities to create a process intensified AAV production process based on perfusion after finding limitations when working with external partners.
With limited assets, startups must rely on CDMO partners. And working with the right ones is imperative even if it comes with a cost.
Lab-grown fish offers a sustainable alternative to current seafood production methods but suffers many of the same manufacturing-based pain points as the biopharma industry, says cultivated fish firm BLUU.
Quality and compliance, customer service levels, financials, health and safety, and environmental sustainability are key to multi-modality manufacturing success, Novartis says.
More from BPI Europe
Upstream & Downstream Processing from BPI Europe
News from BPI Events
More
Assembling the process, equipment, CMC ecosystem, manufacturing network, and talent are the key elements driving Bayer’s allogeneic cell therapy strategy, the firm says.
The overall goal is to work towards a common way of innovating to increase sustainability measures, says firm.
If your CDMO is not willing to change for you then it is time to find someone else, says experts at Biotech Week Boston.
John Crowley told a packed BWB plenary how Amicus Therapeutics is “getting back the magic of biotechnology” and “recapturing the narrative.”
From last year's BPI Europe
More
Talent pool, logistics, and a collaborative ecosystem are three overarching reasons why your CGT firm should invest in the Netherlands.
Synthetic biology could be used to develop a new paradigm in controlling cellular function and specificity, says a bioprocess engineer.
To implement transformation successfully in your company, you must start with the person and not with the technology, says GSK.
Inhouse and outsourcing comes with risks and positives, but according to Bayer a mixture of both capacities is needed.
